Stiris Research Inc. Announces Successful Enrollment Completion in Phase II Retinal Vein Occlusion Study 

London, ON — November 16, 2022 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the enrollment goal reached and participant recruitment closed in a Phase II Retinal Vein Occlusion (RVO) study. 

“This Phase 2 clinical trial reached a key milestone of meeting their enrollment of 60 participants this month thanks in part to the stellar clinical team at Stiris Research that onboarded three Canadian sites in record time.  These sites collectively enrolled seven participants in just a few months contributing to the successful completion of enrollment for this study,” said Sabrina Ramkellawan, Project Manager. 

Retinal vein occlusion (RVO) is a blockage of the small veins that carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain. Retinal vein occlusion is most often caused by hardening of the arteries (atherosclerosis) and the formation of a blood clot. The risk of these disorders increases with age, therefore retinal vein occlusion most often affects older people.  


About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.